Key Issues in Children's Health: Treatment Guidelines for Acute Otitis Media
A supplement to Family Practice News supported by an unrestricted educational grant from Abbott Laboratories.
This supplement was sponsored by Boston University School of Medicine.
The articles are based on presentations that were given at an annual meeting held on November 3, 2003, in New Orleans, LA.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 14.
Faculty
Introduction
Jerome O. Klein, MD, and George H. McCracken, Mr., MD, Co-Chairs
Selecting the Appropriate Antibiotic: The Challenge of Multidrug Resistance
George H. McCracken, Jr., MD
Professor of Pediatrics
University of Texas Southwestern Medical Center
Dallas Clinical Grants: Abbott, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation and Pfizer, Inc. Consultant: Abbott, Aventis Pharmaceuticals Inc., Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly and Company and Novartis. He discusses the unlabeled use of fluoroquinolones for the treatment of acute otitis media.
The Impact of the Pneumococcal Conjugate Vaccine on Otitis Media
Jerome O. Klein, MD
Professor of Pediatrics
Boston University School of Medicine
Boston Medical Center Consultant: MDI Instruments, Inc. and Wyeth Clinical Grants: Wyeth He does not discuss unlabeled/investigational uses.
Observation Without Antibiotics; Need for Pain Management
Jane R. Schwebke, MD
Professor of Medicine
University of Alabama at Birmingham School of Medicine Clinical Grants: 3M Pharmaceuticals, Personal Care Products, Pfizer and Rostam; Consultant: 3M Pharmaceuticals and Rostam.
Current Criteria for Tube Placement and Recommendations for ENT Referral
Charles D. Bluestone, MD
Eberly Professor of Pediatric Otolaryngology
University of Pittsburgh School of Medicine
Children's Hospital of Pittsburgh Nothing to disclose.
Target Audience
Pediatricians, family practitioners, and other health care practitioners who diagnose and treat children with acute otitis media (AOM).
Educational Needs
Acute otitis media (AOM) is one of the most common problems seen in young children in the United States, and it poses a host of diagnostic and management dilemmas. The current clinical milieu is characterized chiefly by the continued threat of antibiotic-resistant organisms and the potential for changes in organisms that are responsible for AOM in the era of universal administration of the heptavalent pneumococcal conjugate vaccine. Clinicians who treat children must be familiar with the evidence that supports the anticipated new guidelines that will be issued by a joint committee of the American Academy of Pediatrics and the American Academy of Family Physicians.
Learning Objectives
By reading and studying this supplement, participants should be able to:
• List the clinical criteria that indicate whether observation is an option for a child with acute otitis media.
• State the antibiotic choices—both preferred and alternative—for treating a child with acute otitis media.
• Discuss the benefits of and indications for placement of tympanostomy tubes.
• Define the criteria for referral of a child with acute otitis media to an ear, nose, and throat specialist.
• Explain the options for pain management of a child with acute otitis media.
• Describe the impact the vaccination program with heptavalent pneumococcal conjugate vaccine has on otitis media.
Accreditation
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent on the activity.
In order to successfully complete this activity, you are required to read the entire monograph and complete and submit the completed test answer sheet by January 31, 2005. CME credit will be awarded provided a score of 70% or better is achieved. A certificate of credit will be sent within six weeks of receipt of the test answers to those who successfully complete the test.
Term of approval: February 1, 2004–January 31, 2005.
